147 related articles for article (PubMed ID: 19231108)
1. Time to treatment in patients with stage III non-small cell lung cancer.
Wang L; Correa CR; Hayman JA; Zhao L; Cease K; Brenner D; Arenberg D; Curtis J; Kalemkerian GP; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):790-5. PubMed ID: 19231108
[TBL] [Abstract][Full Text] [Related]
2. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
[TBL] [Abstract][Full Text] [Related]
3. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
Werner-Wasik M; Scott C; Cox JD; Sause WT; Byhardt RW; Asbell S; Russell A; Komaki R; Lee JS
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1475-82. PubMed ID: 11121651
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer.
Firat S; Bousamra M; Gore E; Byhardt RW
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):1047-57. PubMed ID: 11958901
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
7. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
[TBL] [Abstract][Full Text] [Related]
8. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
Firat S; Byhardt RW; Gore E
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
Rades D; Setter C; Dunst J; Dahl O; Schild SE; Noack F
Strahlenther Onkol; 2010 Jun; 186(6):307-14. PubMed ID: 20437013
[TBL] [Abstract][Full Text] [Related]
10. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
[TBL] [Abstract][Full Text] [Related]
11. Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study.
Maggi G; Casadio C; Cianci R; Oliaro A; Molinatti M; Bretti S; Clerico M; Boidi-Trotti A; Rovea P
J Cardiovasc Surg (Torino); 1994 Aug; 35(4):341-6. PubMed ID: 7929550
[TBL] [Abstract][Full Text] [Related]
12. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Onishi H; Kuriyama K; Yamaguchi M; Komiyama T; Tanaka S; Araki T; Nishikawa K; Ishihara H
Lung Cancer; 2003 Apr; 40(1):79-84. PubMed ID: 12660011
[TBL] [Abstract][Full Text] [Related]
13. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
14. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
15. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.
Movsas B; Scott C; Sause W; Byhardt R; Komaki R; Cox J; Johnson D; Lawton C; Dar AR; Wasserman T; Roach M; Lee JS; Andras E
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1143-9. PubMed ID: 10613306
[TBL] [Abstract][Full Text] [Related]
16. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
17. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery.
Taylor NA; Liao ZX; Stevens C; Walsh G; Roth J; Putnam J; Fossella F; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):616-25. PubMed ID: 12788166
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer.
Fried DV; Tucker SL; Zhou S; Liao Z; Mawlawi O; Ibbott G; Court LE
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):834-42. PubMed ID: 25220716
[TBL] [Abstract][Full Text] [Related]
19. Primary therapeutic decision-making in inoperable non-small cell lung cancer.
Erkurt E; Tunali C; Erkişi M
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):439-44. PubMed ID: 10661352
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer.
Atagi S; Kawahara M; Hosoe S; Ogawara M; Kawaguchi T; Okishio K; Naka N; Sunami T; Mitsuoka S; Akira M
Lung Cancer; 2002 Apr; 36(1):105-11. PubMed ID: 11891041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
